Photocure ASA
OSE:PHO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Photocure ASA
Gross Profit
Photocure ASA
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Photocure ASA
OSE:PHO
|
Gross Profit
kr490.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
16%
|
CAGR 10-Years
15%
|
|
|
V
|
Vistin Pharma ASA
OSE:VISTN
|
Gross Profit
kr300.8m
|
CAGR 3-Years
26%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
N
|
Navamedic ASA
OSE:NAVA
|
Gross Profit
kr220.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
26%
|
CAGR 10-Years
14%
|
|
|
S
|
SoftOx Solutions AS
OSE:SOFTX
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Oncoinvent ASA
OSE:ONCIN
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Photocure ASA
Glance View
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.
See Also
What is Photocure ASA's Gross Profit?
Gross Profit
490.6m
NOK
Based on the financial report for Dec 31, 2025, Photocure ASA's Gross Profit amounts to 490.6m NOK.
What is Photocure ASA's Gross Profit growth rate?
Gross Profit CAGR 10Y
15%
Over the last year, the Gross Profit growth was -1%. The average annual Gross Profit growth rates for Photocure ASA have been 10% over the past three years , 16% over the past five years , and 15% over the past ten years .
